2022 Announcements

Lachlan Hay
Posted by Lachlan Hay
September 5, 2022

CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients

European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 2, 2022

CLINUVEL Kommuniqué IV

Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...

Read More
CLINUVEL
Posted by CLINUVEL
August 31, 2022

CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022

CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar on the financial results for...

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Appendix 4G

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4G

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit

CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Dividend/Distribution – CUV

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Appendix 4E & Annual Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report

Read More
CLINUVEL
Posted by CLINUVEL
August 23, 2022

CLINUVEL Communiqué IV

Melbourne, Australia, 23 August 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 5, 2022

Chair's Letter

In my first letter to you for 2022 I provide updates on...

Read More
CLINUVEL
Posted by CLINUVEL
July 28, 2022

PRÉNUMBRA® for stroke

Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
July 25, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
July 22, 2022

CLINUVEL Kommuniqué III

Seit dem News Communiqué II vom 31. März 2022 hat das Unternehmen...

Read More
CLINUVEL
Posted by CLINUVEL
June 23, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 23, 2022

CLINUVEL Communiqué III

Since News Communiqué II on 31 March 2022, the Company has reported...

Read More
CLINUVEL
Posted by CLINUVEL
June 14, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More